Graybug Vision Inc. (GRAY)
Company Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve.
The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.
The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016.
Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
| Country | United States |
| IPO Date | Sep 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Frederic Guerard |
Contact Details
Address: 203 Redwood Shores Parkway Redwood City, California United States | |
| Website | https://www.graybug.vision |
Stock Details
| Ticker Symbol | GRAY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q103 |
| ISIN Number | US38942Q1031 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frederic Guerard Pharm.D. | Pres, Chief Executive Officer, Sec. & Director |
| Bettina Maunz | Chief People Officer & Head of Communications |
| Robert S. Breuil | Chief Financial Officer & Treasurer |
| Ali Kakavand Ph.D. | Vice President & Head of Program Management |
| Dr. Gerald D. Cagle Ph.D. | Senior Advisor & Head of Bus. Devel. |
| Dr. Parisa Zamiri M.D., Ph.D. | Chief Medical Officer |
| Dr. Peter A. Campochiaro M.D. | Co-Founder |
| Dr. Peter J. McDonnell M.D. | Co-Founder |
| Dr. Ward M. Peterson Ph.D. | Senior Vice President of Preclinical Devel. |
| Han Wettenstein | Vice President & Controller |
| Ming Yang | Senior Vice President of R&D |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Sep 02, 2025 | 4 | Filing |
| Aug 25, 2025 | 4 | Filing |
| Aug 21, 2025 | 4 | Filing |
| Aug 21, 2025 | 4 | Filing |
| Aug 19, 2025 | 4 | Filing |
| Aug 18, 2025 | 4 | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |